Since most of hematologic malignancies caused by precursor B or T cells, T cell therapy using chimeric antigen receptors to target only those tumor cells such as CD19 CAR T cell therapy for CLL and ALL CD19, CD20, CD30 CAR T therapy for lymphoma, and CD19, BCMA for MM, CD30 in HL [21–24] shows an encouragement towards future oncogenic treatment processes. Here, CD19 is linked to acute lymphoblastic leukemia.